Pharmacoeconomic Evaluation of Antidiabetic Agents-Metformin Plus Teneligliptin Versus Metformin Plus Glimepiride-A Prospective Study
Nimmy N John*, Arjun V J, Darath David, H. Doddayya.
N.E.T. Pharmacy College, Raichur- 584103, Karnataka,
Diabetes mellitus is a metabolic-cum-vascular disorder of numerous etiologies described by constant hyperglycemia with aggravations of sugar, fat and protein digestion coming about deformities in insulin emission, insulin activity or both. This issue is every now and again connected with long haul harm, which can prompt disappointment of organs like eyes, kidney, nerves, heart and veins.. In India, diabetes mellitus is influencing 33% of the grown-up populace. It is basically connected with wellbeing trouble just as high financial weight at individual and populace levels. A forthcoming observational investigation was completed in-patients confessed to general medication division of NMCH&RC determined to have diabetes mellitus endorsed with combination treatment of Metformin + Glimepiride and combination treatment of Metformin + Teneligliptin from September 2019 to February 2020. Information was gathered from case sheets of patients and evaluated for their monetary weight dependent on the expense per tablet for long term. Cost viability proportion for the patients with controlled blood glucose level by utilizing a specific medication was determined and likelihood to lessen the diabetes mellitus was assessed. Among 70 in-patients, 38 patients (54.29%) were males and 32 patients (45.71%) were females. Patients are between the age gathering of 41-60 years were more (48.57%). Majority of the patients were conceded with known history of diabetes mellitus (81.43%). A large portion of the patients were endorsed with combination treatment of Metformin + Glimepiride (81.42%) followed with Metformin + Teneligliptin (18.57%). There was a critical positive connection (i.e., p value= 0.5607) between perseverance examples of patients with drug treatment. Likelihood of patients taking combination treatment of Metformin + Glimepiride was 77.19% trailed by patients with combination treatment of Metformin + Teneligliptin. Combination treatment of Metformin + Glimepiride are having more Cost adequacy proportion. This investigation obviously indicated that combination treatment of Metformin + Glimepiride is the most practical treatment among other combination treatment to lessen monetary weight to the patient just as to diminish the entanglements. Pharmacoeconomic assessments can help in creation troublesome decisions judiciously and designate scant assets productively.
mellitus, Treatment Pharmacoeconomics, Cost effectiveness, Hyperglycaemia